Farxiga (Dapagliflozin) Cost in Alabama: Prices, Insurance, and Savings in 2026

What Does Farxiga Cost at Alabama Pharmacies in 2026?

The average cash price for brand-name Farxiga at Alabama retail pharmacies is $620 per month for a 30-day supply of 10 mg tablets. This price reflects the AstraZeneca manufacturer list price and is consistent across most chain pharmacies in the state, though minor variations exist between independent pharmacies in Birmingham, Huntsville, Mobile, and Montgomery.

Dapagliflozin is an SGLT2 inhibitor that the FDA first approved in 2014 for type 2 diabetes. The drug has since earned expanded indications for heart failure and chronic kidney disease, making it one of the most broadly indicated cardiorenal medications available [1]. Without insurance, the annual cost exceeds $7,400. No generic version of dapagliflozin is available in the United States as of May 2026, as AstraZeneca's patent protections remain active. The DECLARE-TIMI 58 trial (N=17,160) established the cardiovascular safety profile that underpins many of these indications, showing a 17% reduction in cardiovascular death or hospitalization for heart failure versus placebo [2].

Alabama ranks among the states with the highest rates of type 2 diabetes. According to CDC data, approximately 15.1% of Alabama adults have diagnosed diabetes, compared to the national average of 11.6% [3]. This prevalence makes access to SGLT2 inhibitors a significant public health concern for the state.

Does Alabama Medicaid Cover Farxiga?

Alabama Medicaid does not currently list Farxiga on its preferred drug formulary. Patients enrolled in Alabama Medicaid who need dapagliflozin face a non-preferred status, which means prescribers must submit prior authorization documentation and demonstrate that preferred agents (typically metformin, sulfonylureas, or preferred DPP-4 inhibitors) were tried first or are contraindicated.

The ADA Standards of Care (2024) recommend SGLT2 inhibitors as first-line add-on therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of A1C level [4]. This guideline positioning creates a clinical tension with Alabama Medicaid's formulary restrictions. Prescribers can cite these ADA guidelines as supporting evidence when filing prior authorization appeals [5].

For patients with heart failure specifically, the case for coverage is strong. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) compared to placebo, regardless of diabetes status [6]. The DELIVER trial (N=6,263) extended this benefit to patients with heart failure and preserved ejection fraction, showing a 18% reduction in the same composite endpoint [7].

Alabama Medicaid patients who receive a denial should request a "fair hearing" through the Alabama Medicaid Agency within 30 days. Attach the prescriber's clinical rationale, relevant lab results, and guideline citations.

Which Commercial Insurance Plans Cover Farxiga in Alabama?

Most commercial insurance plans available in Alabama cover Farxiga, though placement varies between formulary tiers. Blue Cross Blue Shield of Alabama, the state's largest insurer, generally places Farxiga on its specialty or non-preferred brand tier, requiring a copay between $50 and $150 per month after prior authorization. UnitedHealthcare, Aetna, and Humana plans sold on the Alabama exchange follow similar patterns.

Prior authorization criteria across these plans typically require documentation of one or more of the following: a diagnosis of type 2 diabetes with inadequate glycemic control on metformin, established heart failure (NYHA class II-IV), or chronic kidney disease with eGFR between 25 and 75 mL/min/1.73 m². The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the risk of sustained decline in eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death by 39% (HR 0.61, P<0.001) [8]. Insurers increasingly recognize this renal benefit data.

The KDIGO 2024 Clinical Practice Guideline for CKD now recommends SGLT2 inhibitors for all patients with CKD at risk of progression, with or without diabetes [9]. Citing this guideline can strengthen prior authorization requests. The ACC/AHA heart failure guidelines similarly list SGLT2 inhibitors as a class I recommendation for heart failure management across ejection fraction categories [10]. Patients with Medicare Part D coverage in Alabama may also have access, though the specific tier and out-of-pocket cost depend on the plan sponsor.

How Does the AstraZeneca Savings Card Work in Alabama?

The AstraZeneca savings card for Farxiga is available to commercially insured Alabama residents. It can reduce the monthly copay to as low as $0 for eligible patients. The card covers up to $300 per 30-day fill, and patients can use it for up to 24 months.

Eligibility requires commercial (private) insurance. Patients on Medicare, Medicaid, Tricare, or other federal or state government programs do not qualify. To activate the card, patients visit the manufacturer's program portal, enter their insurance information, and receive a digital or physical card. Present it at any Alabama pharmacy alongside the insurance card. The pharmacist processes the insurance claim first, then applies the savings card to the remaining copay.

For uninsured Alabama patients, AstraZeneca also offers the AZ&ME prescription savings program, which may provide Farxiga at no cost to qualifying individuals with household incomes below 400% of the federal poverty level [11]. A single individual earning less than approximately $62,400 annually would meet this threshold in 2026. Application requires proof of income, Alabama residency, and a valid prescription.

Is Compounded Dapagliflozin Legal in Alabama?

Compounded dapagliflozin is legal in Alabama through licensed 503A compounding pharmacies. Alabama follows the federal framework established under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding by state-licensed pharmacies operating under valid prescriptions [12].

A 503A pharmacy in Alabama can compound dapagliflozin when a prescriber writes a patient-specific prescription. The compounded product is not FDA-approved and does not undergo the same manufacturing quality controls as brand-name Farxiga. Patients should verify that the compounding pharmacy holds a current Alabama Board of Pharmacy license and is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or a similar body.

Compounded dapagliflozin pricing in Alabama varies by pharmacy but is typically lower than the $620 brand-name price. Some 503A pharmacies offer compounded SGLT2 inhibitor formulations for substantially reduced cost. Patients considering this route should discuss bioequivalence considerations with their prescriber, as compounded formulations may differ in excipients, dissolution rates, and stability from the FDA-approved Farxiga formulation [13].

The FDA has issued guidance distinguishing legitimate compounding from manufacturing [14]. A pharmacy that produces large batches without patient-specific prescriptions operates outside 503A protections. Alabama patients should confirm their compounding pharmacy prepares each order individually.

Can I Get Farxiga via Telehealth in Alabama?

Alabama permits telehealth prescribing of Farxiga. The Alabama Board of Medical Examiners allows physicians to establish patient relationships and prescribe medications through audio-video telehealth encounters. Dapagliflozin is not a controlled substance, so it faces no additional telehealth prescribing restrictions beyond standard practice requirements.

A telehealth visit for Farxiga typically involves review of the patient's medical history, recent lab work (A1C, eGFR, potassium, blood pressure), and assessment of the clinical indication. The prescriber can send the prescription electronically to any Alabama retail or compounding pharmacy. Baseline labs should include a complete metabolic panel, as SGLT2 inhibitors carry a known risk of diabetic ketoacidosis (DKA), even at normal glucose levels. The FDA safety communication on SGLT2 inhibitor-associated DKA recommends monitoring for symptoms including nausea, vomiting, abdominal pain, and malaise [15].

Telehealth prescribers should also assess for genital mycotic infection risk, which occurred in approximately 6.9% of dapagliflozin-treated patients versus 1.5% on placebo in the DECLARE-TIMI 58 safety analysis [2]. Volume depletion is another consideration, particularly relevant in Alabama's humid subtropical climate. Patients on loop diuretics or those with eGFR <45 mL/min/1.73 m² may need dose adjustments of concomitant medications. The Endocrine Society clinical guidance on SGLT2 inhibitors recommends holding the drug during acute illness, surgery, or prolonged fasting to reduce DKA risk [16].

How to Reduce Your Farxiga Cost in Alabama

Multiple strategies can lower out-of-pocket expenses for Alabama patients. The approach depends on insurance status.

Commercially insured patients should start with the AstraZeneca savings card. Combined with insurance, most patients pay $0 to $50 per month. If the formulary requires step therapy, the prescriber can file a medical exception citing ADA recommendations for SGLT2 inhibitors in patients with cardiorenal comorbidities [4].

Uninsured patients should apply for the AZ&ME patient assistance program. If ineligible, compounded dapagliflozin through a licensed Alabama 503A pharmacy provides the lowest cost alternative. Alabama has several accredited compounding pharmacies in Birmingham, Huntsville, and Mobile.

Medicare Part D enrollees should compare plan formularies during open enrollment (October 15 through December 7). Some Medicare Advantage plans in Alabama place Farxiga on preferred brand tiers with copays of $47 to $100 per month. The 2025 Inflation Reduction Act provisions cap annual out-of-pocket Part D spending at $2,000, which may reduce total annual Farxiga costs for high-utilization patients [17].

Alabama Medicaid enrollees should work with their prescriber to file prior authorization with clinical documentation. Include the specific indication (heart failure, CKD, or type 2 diabetes with cardiorenal risk), the relevant trial data from DAPA-HF [6] or DAPA-CKD [8], and documentation of prior therapies tried.

Clinical Indications That Support Coverage

Insurance approval rates improve when the prescribed indication aligns with FDA-approved uses and guideline recommendations. Dapagliflozin carries three distinct FDA approvals.

For type 2 diabetes, Farxiga 10 mg once daily as adjunct to diet and exercise reduces A1C by approximately 0.7% to 0.8% as monotherapy. The FDA-approved labeling permits use alone or in combination with other glucose-lowering agents [1].

For heart failure, the FDA expanded the indication in May 2020 to include adults with heart failure with reduced ejection fraction (NYHA class II-IV) to reduce cardiovascular death and hospitalization [18]. The DAPA-HF trial enrolled patients with LVEF <40% and showed benefit regardless of diabetes status, with a number needed to treat (NNT) of 21 over 18.2 months to prevent one primary endpoint event.

For chronic kidney disease, the FDA approved dapagliflozin in April 2021 for patients at risk of progression, based on the DAPA-CKD results [19]. The trial included patients with eGFR 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200 to 5,000 mg/g.

Dr. Hiddo Heerspink, lead author of the DAPA-CKD trial, stated: "The renal benefits of dapagliflozin were consistent regardless of the presence or absence of type 2 diabetes, suggesting the mechanism of kidney protection extends beyond glucose lowering" [8].

A Cochrane systematic review of SGLT2 inhibitors confirmed a class-wide reduction in kidney failure events (RR 0.73, 95% CI 0.68 to 0.79) across multiple trials involving over 90,000 participants [20].

Alabama prescribers submitting prior authorization should specify which of these three indications applies, as each triggers different formulary pathways.

Dapagliflozin Dosing and Monitoring for Alabama Providers

Standard dosing is 10 mg once daily, taken in the morning with or without food. No dose titration is required. For patients with eGFR <25 mL/min/1.73 m², initiation is not recommended per the FDA label, though patients already on the drug who reach this threshold can continue [1].

Monitoring should include eGFR at baseline and periodically thereafter. An initial eGFR "dip" of 10% to 30% is expected within the first two weeks and is hemodynamically mediated, not indicative of kidney injury. The CREDENCE ancillary analysis published in JASN (examining the related SGLT2 inhibitor canagliflozin) confirmed this acute dip reverses after discontinuation, supporting a tubuloglomerular feedback mechanism rather than structural damage [21]. Blood pressure typically decreases by 3 to 5 mmHg systolic, and body weight may decrease by 2 to 3 kg within 6 months.

Alabama providers should counsel patients on the signs of genital mycotic infections and urinary tract infections, maintain adequate hydration (especially during Alabama summers), and hold the medication 3 days before scheduled surgery. Check serum potassium if combining with ACE inhibitors, ARBs, or potassium-sparing diuretics. The WHO Model List of Essential Medicines added dapagliflozin in 2023, underscoring its global significance for cardiorenal protection [22].